Publicacións en colaboración con investigadores/as de Hospital Virgen del Camino (47)

2023

  1. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

  2. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

  3. What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  2. SEOM-TTCC clinical guideline in nasopharynx cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 670-680

2021

  1. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1272-1280

  2. Controversies in the treatment of RAS wild-type metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839

  3. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  4. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

    Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456

  5. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

    ESMO Open, Vol. 6, Núm. 2

  6. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

    Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936

  7. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

  8. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 988-1000

2020

  1. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

    Lung Cancer, Vol. 150, pp. 90-96

  2. Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2020), 22, 6, (823-834), 10.1007/s12094-019-02211-x)

    Clinical and Translational Oncology

  3. Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer: The avamet study

    Cancers, Vol. 12, Núm. 8, pp. 1-12

  4. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?

    International Journal of Colorectal Disease, Vol. 35, Núm. 4, pp. 739-746

  5. Liquid biopsy in oncology: A consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 53, Núm. 4, pp. 234-245

  6. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 823-834

  7. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654